MedDataX Logo

Shanghai Lymphoma Clinical Cohort

NCT ID: NCT07285174

Last Updated: 2025-12-16

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Total Enrollment

1000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-12-18

Study Completion Date

2029-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this study is to prospectively collect clinical information on patients with lymphoma, and to explore the best therapeutic strategies in the real-world population.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Lymphoma is a common hematological malignancy. This study aims to prospectively collect clinical information on patients with lymphoma, including the distribution of involved sites, clinical and molecular characteristics of different lymphoma subtypes, clinical treatment protocols, and prognosis, to explore the best therapeutic strategies in the real-world population.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lymphoma Cohort

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Shanghai Lymphoma Clinical Cohort

Shanghai Lymphoma Clinical Cohort

No interventions need to be specified for this study

Intervention Type OTHER

No interventions need to be specified for this study

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

No interventions need to be specified for this study

No interventions need to be specified for this study

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Age ≥ 16 years (including 16 years old).
2. Patients newly diagnosed with non-Hodgkin lymphoma
3. Patients who have received systematic clinical treatment.
4. Patients with measurable lesions, at least containing one effective evaluation of efficacy.

Exclusion Criteria

1. Patients who only receive supportive treatment.
2. Patients who cannot obtain effective evaluation data of efficacy.
Minimum Eligible Age

16 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Ruijin Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Zhao Weili

Dean

Responsibility Role PRINCIPAL_INVESTIGATOR

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Weili Zhao, MD, PhD

Role: CONTACT

[email protected]
+862164370045 ext. Ext. 610707

Pengpeng Xu, MD

Role: CONTACT

[email protected]
+862164370045 ext. Ext. 610707

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Shanghai Lymphoma Cohort

Identifier Type: -

Identifier Source: org_study_id